Effect of Intraperitoneal ATP on Tumor Growth and Bone Marrow Radiation Tolerance

Authors

  • John Froio Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA
  • Edward H. Abraham Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA
  • Rajesh Soni Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA
  • Alan Epstein Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA
  • Paul Okunieff Radiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA

DOI:

https://doi.org/10.3109/02841869509094001

Abstract

Transplants of a spontaneous murine fibrosarcoma (FSaII) treated with intraperitoneal ATP were studied in vitro, and in both C3H and nu/nu mice. Daily ATP treatment prolonged tumor volume doubling time in vivo and in vitro. Daily ATP treatments at the maximally tolerated dose (2 mmol/kg i.p.) did not significantly affect the pH or the PCr/Pi, or βATP/Pi ratios (measured by MRS). In contrast to the reduced tumor growth rate, there was no change in bone marrow recovery after whole body irradiation. ATP is minimally toxic to animals at active dose levels. It slows tumor growth rate without adversely affecting bone marrow radiation tolerance. ATP might therefore be useful as a biological modifier of chemotherapy or radiation therapy.

Downloads

Download data is not yet available.

Downloads

Published

1995-01-01

How to Cite

Froio, J., Abraham, E. H., Soni, R., Epstein, A., & Okunieff, P. (1995). Effect of Intraperitoneal ATP on Tumor Growth and Bone Marrow Radiation Tolerance. Acta Oncologica, 34(3), 419–422. https://doi.org/10.3109/02841869509094001

Issue

Vol. 34 No. 3 (1995): Acta Oncologica

Section

Articles